牛牛AI助理已提取核心訊息
On February 2, 2024, NexImmune, Inc., a biotechnology company listed on Nasdaq under the ticker NEXI, announced a registered direct offering and a concurrent private placement expected to raise approximately $3.67 million. The offering, priced at-the-market under Nasdaq rules, involves the sale of 117,000 shares of common stock at $12.05 per share and pre-funded warrants exercisable for up to 187,731 shares at $12.049 per warrant. Additionally, unregistered warrants to purchase up to 304,731 shares of common stock at $12.05 per share are being offered in the private placement. The closing of the offerings is anticipated on February 6, 2024, subject to customary conditions. The company has agreed to certain restrictions on stock issuance for 20 days post-closing. H.C. Wainwright & Co. is acting as the exclusive placement agent...Show More
On February 2, 2024, NexImmune, Inc., a biotechnology company listed on Nasdaq under the ticker NEXI, announced a registered direct offering and a concurrent private placement expected to raise approximately $3.67 million. The offering, priced at-the-market under Nasdaq rules, involves the sale of 117,000 shares of common stock at $12.05 per share and pre-funded warrants exercisable for up to 187,731 shares at $12.049 per warrant. Additionally, unregistered warrants to purchase up to 304,731 shares of common stock at $12.05 per share are being offered in the private placement. The closing of the offerings is anticipated on February 6, 2024, subject to customary conditions. The company has agreed to certain restrictions on stock issuance for 20 days post-closing. H.C. Wainwright & Co. is acting as the exclusive placement agent, receiving a cash fee and warrants as compensation. The proceeds are intended for financing, business development, collaboration opportunities, working capital, and general corporate purposes. This announcement has led to the postponement of a special meeting of stockholders initially set for February 7, 2024, which was to vote on the company's liquidation and dissolution.
2024年2月2日，在納斯達克上市的股票代碼爲NEXI的生物技術公司NexImmune, Inc. 宣佈註冊直接發行，並同時進行私募配售，預計將籌集約367萬美元。此次發行根據納斯達克規則在市場上定價，涉及以每股12.05美元的價格出售11.7萬股普通股，以及以每份認股權證12.049美元的價格行使最多187,731股的預籌認股權證。此外，還通過私募發行了未註冊的認股權證，以每股12.05美元的價格購買多達304,731股普通股。此次發行預計將於2024年2月6日結束，但須遵守慣例條件。該公司已同意在收盤後20天內對股票發行實行某些限制。H.C. Wainwright & Co. 擔任獨家配售代理，收取現金費和認股權證作爲補償。所得款項用於融資、業務發展、合作機會、營運資金和一般公司用途。該公告導致原定於2024年2月7日舉行的股東特別會議推遲，該會議將對公司的清算和解散進行投票。
2024年2月2日，在納斯達克上市的股票代碼爲NEXI的生物技術公司NexImmune, Inc. 宣佈註冊直接發行，並同時進行私募配售，預計將籌集約367萬美元。此次發行根據納斯達克規則在市場上定價，涉及以每股12.05美元的價格出售11.7萬股普通股，以及以每份認股權證12.049美元的價格行使最多187,731股的預籌認股權證。此外，還通過私募發行了未註冊的認股權證，以每股12.05美元的價格購買多達304,731股普通股。此次發行預計將於2024年2月6日結束，但須遵守慣例條件。該公司已同意在收盤後20天內對股票發行實行某些限制。H.C. Wainwright & Co. 擔任獨家配售代理，收取現金費和認股權證作爲補償。所得款項用於融資、業務發展、合作機會、營運資金和一般公司用途。該公告導致原定於2024年2月7日舉行的股東特別會議推遲，該會議將對公司的清算和解散進行投票。
有用
沒用
